Sanofi position in ANAB
ANAPTYSBIO INC · Health Care
Sanofi reported holding 821,917 shares of ANAB (ANAPTYSBIO INC) in its Q3 2026 13F filing — a position valued at US$41.3M, representing 6.56% of its reported portfolio and ranking #6 among its reported holdings. Sanofi has disclosed ANAB holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-05 · Source: SEC EDGAR Form 13F-HR
How Sanofi's ANAB position evolved
Sanofi first disclosed a stake in ANAB in Q4 2024 at 821,917 shares (US$10.9M). The position peaked in Q2 2026 at 821,917 shares, worth US$55.5M. Across 8 filings, Sanofi held the position steady without any share-count change. The most recent filing (Q3 2026) shows 821,917 shares valued at US$41.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 821.92K | $10.88M | New |
| Q1 2025 | 821.92K | $15.28M | Hold |
| Q2 2025 | 821.92K | $18.25M | Hold |
| Q3 2025 | 821.92K | $25.17M | Hold |
| Q4 2025 | 821.92K | $39.85M | Hold |
| Q1 2026 | 821.92K | $30.38M | Hold |
| Q2 2026 | 821.92K | $55.48M | Hold |
| Q3 2026 | 821.92K | $41.31M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ANAB and 13F data
ANAB (ANAPTYSBIO INC) is a Health Care company. 46 other funds we track also report a position in ANAB — the largest reported positions include EcoR1 Capital, LLC (US$531.9M), TANG CAPITAL MANAGEMENT LLC (US$89.8M), Affinity Asset Advisors, LLC (US$55.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ANAB
- EcoR1 Capital, LLC 7.88M sh · $531.91M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.33M sh · $89.83M · Q2 2026
- Affinity Asset Advisors, LLC 826.11K sh · $55.76M · Q2 2026
- 683 Capital Management, LLC 660.00K sh · $44.55M · Q2 2026
- Palo Alto Investors LP 603.49K sh · $40.74M · Q2 2026
- First Light Asset Management, LLC 582.00K sh · $39.29M · Q2 2026
- APIS CAPITAL ADVISORS, LLC 497.00K sh · $33.55M · Q2 2026
- Sofinnova Investments, Inc. 493.54K sh · $33.31M · Q2 2026
- Coppell Advisory Solutions LLC 3.64K sh · $16.58M · Q2 2026
- Greenhaven Road Investment Management, L.P. 171.06K sh · $11.55M · Q2 2026
FAQ
How long has Sanofi held ANAB?
Sanofi has disclosed ANAB holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Sanofi's current position in ANAB?
As of Q3 2026, Sanofi holds 821.92K shares of ANAB (ANAPTYSBIO INC), valued at $41.31M, representing 6.56% of its reported portfolio and ranking #6.
Has Sanofi been buying or selling ANAB?
In the latest 13F filing (Q3 2026), Sanofi held unchanged its position in ANAB. The position peaked in Q2 2026 at 821.92K shares.
Which other funds hold ANAB?
Other major institutional holders of ANAB include EcoR1 Capital, LLC, TANG CAPITAL MANAGEMENT LLC, Affinity Asset Advisors, LLC, among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.